Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system

被引:13
|
作者
Caberlotto, Laura [1 ]
Carboni, Lucia [1 ]
Zanderigo, Floriana [1 ]
Andreetta, Filippo [1 ]
Andreoli, Michela [1 ]
Gentile, Gabriella [1 ]
Razzoli, Maria [1 ]
机构
[1] GlaxoSmithKline Med Res Ctr, Neurosci CEDD, I-37135 Verona, Italy
关键词
Amphetamine-induced hyperlocomotion; Blood BDNF levels; Blood hormone levels; CRMP2; GSK3; inhibitors; Lithium; RESPONSE MEDIATOR PROTEINS; ELEMENT-BINDING PROTEIN; NEUROTROPHIC FACTOR; INDUCED HYPERACTIVITY; MOOD STABILIZERS; SODIUM VALPROATE; GROWTH-HORMONE; BETA-CATENIN; BRAIN; PHOSPHORYLATION;
D O I
10.1007/s00210-013-0893-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glycogen synthase kinase (GSK3) is a constitutively active serine-threonine kinase associated to neurological and psychiatric disorders. GSK3 inhibition is considered a mediator of the efficacy of the mood-stabiliser lithium. This study aimed at comparing the central nervous system effect of lithium with the selective GSK3 inhibitors AZ1080 and compound A in biochemical, cellular, and behavioural tests. Collapsin response mediator protein 2 is a neuron-specific GSK3 substrate. Lithium, AZ1080, and compound A inhibited its phosphorylation in rat primary neurons with different pIC(50). After systemic treatments with lithium or GSK3 inhibitors to assess specific functional responses, phosphorylation was unchanged in adult rat brain, while it was strongly inhibited by GSK3 inhibitors in pups, differently from lithium. Lithium may exert neurotrophic effect by increasing brain-derived neurotrophic factor (BDNF) levels: in the present experimental conditions, lithium exerted opposite effects on plasma BDNF levels compared to GSK3 inhibitors, suggesting this effect might not be necessarily mediated by GSK3 inhibition alone. While plasma thyroid-stimulating hormone and luteinising hormone were not affected by lithium, they were decreased by selective inhibitors. GH and prolactin displayed similar responses towards reduction. Follicle-stimulating hormone levels were not altered by treatments, whereas melatonin was specifically increased by AZ1080. Lithium impaired mouse spontaneous locomotion and decreased amphetamine-induced hyper-locomotion. AZ1080 had no effects on locomotion, while compound A reduced spontaneous locomotor activity without effects on amphetamine-induced hyper-locomotion. The present results indicate that a broad correlation between the effects of lithium and selective GSK3 inhibitors could not be devised, suggesting alternative mechanisms, whereas overlapping results could be obtained in specific assays.
引用
收藏
页码:893 / 903
页数:11
相关论文
共 50 条
  • [1] Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system
    Laura Caberlotto
    Lucia Carboni
    Floriana Zanderigo
    Filippo Andreetta
    Michela Andreoli
    Gabriella Gentile
    Maria Razzoli
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386 : 893 - 903
  • [2] Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors
    Wadhwa, Pankaj
    Jain, Priti
    Jadhav, Hemant R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (17) : 1522 - 1534
  • [3] Age-related changes in glycogen synthase kinase 3β (GSK3β) immunoreactivity in the central nervous system of rats
    Lee, Soo Joo
    Chung, Yoon Hee
    Joo, Kyeung Min
    Lim, Heon Chang
    Jeon, Gye Sun
    Kim, Daejin
    Lee, Won Bok
    Kim, Yong Sik
    Cha, Choong Ik
    NEUROSCIENCE LETTERS, 2006, 409 (02) : 134 - 139
  • [4] Glycogen synthase kinase-3 (GSK3) inhibition by lithium induces O-GlcNAcylation perturbations
    Wang, Zihao
    Hart, Gerald
    FASEB JOURNAL, 2007, 21 (06): : A1021 - A1021
  • [5] A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
    Thapa, Riya
    Gupta, Gaurav
    Bhat, Asif Ahmad
    Almalki, Waleed Hassan
    Alzarea, Sami I.
    Kazmi, Imran
    Saleem, Shakir
    Khan, Ruqaiyah
    Altwaijry, Najla
    Dureja, Harish
    Singh, Sachin Kumar
    Dua, Kamal
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 253
  • [6] Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy
    Luo, Jia
    CANCER LETTERS, 2009, 273 (02) : 194 - 200
  • [7] GSK3 as a pathogenic kinase in tauopathy and the use of GSK3 inhibitors such as Lithium as a therapeutic
    Duff, Karen
    Planel, Emmanuel
    Noble, Wendy
    MOVEMENT DISORDERS, 2008, 23 (08) : 1197 - 1197
  • [8] Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer’s disease
    Dipanjan Karati
    Shreyasi Meur
    Souvik Roy
    Swarupananda Mukherjee
    Biplab Debnath
    Sajal Kumar Jha
    Biresh Kumar Sarkar
    Saheli Naskar
    Priya Ghosh
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2025, 398 (3) : 2319 - 2342
  • [9] Inhibition of Glycogen Synthase Kinase 3β (GSK3β) Decreases Inflammatory Responses in Brain Endothelial Cells
    Ramirez, Servio H.
    Fan, Shongshan
    Zhang, Ming
    Papugani, Anil
    Reichenbach, Nancy
    Dykstra, Holly
    Mercer, Aaron J.
    Tuma, Ronald F.
    Persidsky, Yuri
    AMERICAN JOURNAL OF PATHOLOGY, 2010, 176 (02): : 881 - 892
  • [10] The Role of Glycogen Synthase Kinase 3 (GSK3) in Regulating Intracellular Transport
    Nabti, Ibtissem
    Shubeita, George T.
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 431A - 431A